Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit–Harm Assessments-Reference-Cited by-同舟云学术

Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit–Harm Assessments

Published:2020-05 Issue:5 Volume:23 Page:616-624
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Aschmann Hélène E.,Boyd Cynthia M.,Robbins Craig W.,Chan Wiley V.,Mularski Richard A.,Bennett Wendy L.,Sheehan Orla C.,Wilson Renée F.,Bayliss Elizabeth A.,Leff Bruce,Armacost Karen,Glover Carol,Maslow Katie,Mintz Suzanne,Puhan Milo A.

Funder

Patient-Centered Outcomes Research Institute

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference37 articles.

1. Patient-centered outcomes research and patient-centered care for older adults;Jayadevappa;Gerontol Geriatr Med,2017

2. Finding the balance between benefits and harms when using statins for the primary prevention of cardiovascular disease: a modeling study;Yebyo;Ann Intern Med,2019

3. A framework for organizing and selecting quantitative approaches for benefit-harm assessment;Puhan;BMC Med Res Methodol,2012

4. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer;Gail;J Natl Cancer Inst,1999

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living bene fi t - harm modelling study;ECLINICALMEDICINE;2024

2. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study;eClinicalMedicine;2024-07

3. Is Statistical Significance Alone Obsolete? – Let’s Turn to Meaningful Interpretation of Scientific and Real-world Evidence on Surgical Care;Annals of Surgery;2024-03-20

4. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment;European Urology Oncology;2022-12

5. Fingolimod versus interferon beta 1-a: Benefit–harm assessment approach based on TRANSFORMS individual patient data;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2022-07